Janice H. Jou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Janice H. Jou has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Adam C. Winters
Recanati/Miller Transplantation Institute, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA
1 shared publication Andrew J. Muir
∥Division of Gastroenterology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
1 shared publication- Ang Li
Section of Hematology-Oncology, Baylor College of Medicine , Houston, TX
1 shared publication Barry Schlansky
Department of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon, USA
1 shared publicationBen Hornung
Department of Internal Medicine, Oregon Health and Science University, Portland, Oregon, USA
1 shared publicationCharles K Enestvedt
Department of Abdominal Transplantation Surgery, Oregon Health and Science University, Portland, Oregon, USA
1 shared publication
Latest Publications
- 15 July 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (11) , 1200-1202
Evolution of the transplant hepatology fellowship application process and its impact on the future of the hepatology workforce
An abstract is unavailable. This article is available as a PDF only.
- 15 July 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (11) , 1200-1202
Evolution of the transplant hepatology fellowship application process and its impact on the future of the hepatology workforce
An abstract is unavailable. This article is available as a PDF only.
- 1 November 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (5) , 157-161
Updates in nonalcoholic fatty liver disease
Export
- 1 November 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (5) , 157-161
Updates in nonalcoholic fatty liver disease
Export
- Open Access
- 1 August 2021
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 18 (2) , 76-80
Systemic Sclerosis and the Liver
- 1 August 2021
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 18 (2) , 76-80
Open AccessSystemic Sclerosis and the Liver
- Open Access
- 18 January 2021
- Published by Taylor & Francis in Platelets
- Vol. 33 (1) , 66-72
The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis
Thrombopoietin receptor agonists (TPO-RAs) can mitigate preprocedural thrombocytopenia in patients with chronic liver disease (CLD) however their effects on procedural outcomes is unclear. In this meta-analysis, we aimed to better define the efficacy, thrombotic risk and bleeding mitigation associated with the use of preoperative TPO-RAs in patients with CLD. We performed a systematic review and meta-analysis of randomized placebo-controlled clinical trials to assess the use of preprocedural TPO-RAs in patients with CLD, searching MEDLINE, EMBASE and the Cochrane library database. Six publications comprising eight randomized trials (1229 patients; 717 received TPO-RAs, 512 received placebo) and three unique TPO-RAs were retrieved. The majority of the included procedures were endoscopic. TPO-RAs were significantly more likely to result in a preoperative platelet count greater than 50 x 109/L (72.1% vs 15.6%, RR 4.8, 95% CI 3.6–6.4 p < .00001. NNT 1.8) and reduced the incidence of platelet transfusions (22.5% vs 67.8%, RR 0.33, 95% CI 0.3–0.4 p < .00001. NNT 2.2). Total periprocedural bleeding was decreased in patients who received TPO-RAs (11.6% vs 15.6%, RR 0.64, 95% CI 0.5–0.9 p = .01. NNT 24.7) and there was no increase in the rate of thrombosis (2.2% vs 1.8% RR 1.25, 95% CI 0.6–2.9 p = .60. NNH 211.1). In patients with CLD the use of preprocedural TPO-RAs resulted in significant increased platelet counts, and decreased the incidence of platelet transfusions as compared to placebo. TPO use likewise decreased the incidence of total periprocedural bleeding without increasing the rate of thrombosis.
- 18 January 2021
- Published by Taylor & Francis in Platelets
- Vol. 33 (1) , 66-72
Open AccessThe efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis
Thrombopoietin receptor agonists (TPO-RAs) can mitigate preprocedural thrombocytopenia in patients with chronic liver disease (CLD) however their effects on procedural outcomes is unclear. In this meta-analysis, we aimed to better define the efficacy, thrombotic risk and bleeding mitigation associated with the use of preoperative TPO-RAs in patients with CLD. We performed a systematic review and meta-analysis of randomized placebo-controlled clinical trials to assess the use of preprocedural TPO-RAs in patients with CLD, searching MEDLINE, EMBASE and the Cochrane library database. Six publications comprising eight randomized trials (1229 patients; 717 received TPO-RAs, 512 received placebo) and three unique TPO-RAs were retrieved. The majority of the included procedures were endoscopic. TPO-RAs were significantly more likely to result in a preoperative platelet count greater than 50 x 109/L (72.1% vs 15.6%, RR 4.8, 95% CI 3.6–6.4 p < .00001. NNT 1.8) and reduced the incidence of platelet transfusions (22.5% vs 67.8%, RR 0.33, 95% CI 0.3–0.4 p < .00001. NNT 2.2). Total periprocedural bleeding was decreased in patients who received TPO-RAs (11.6% vs 15.6%, RR 0.64, 95% CI 0.5–0.9 p = .01. NNT 24.7) and there was no increase in the rate of thrombosis (2.2% vs 1.8% RR 1.25, 95% CI 0.6–2.9 p = .60. NNH 211.1). In patients with CLD the use of preprocedural TPO-RAs resulted in significant increased platelet counts, and decreased the incidence of platelet transfusions as compared to placebo. TPO use likewise decreased the incidence of total periprocedural bleeding without increasing the rate of thrombosis.
- Top Cited PapersOpen Access
- 1 January 2021
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 17 (1) , 23-28
Nonalcoholic Fatty Liver Disease and Recent Guideline Updates
Watch a video presentation of this article
- 1 January 2021
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 17 (1) , 23-28
Top Cited PapersOpen AccessNonalcoholic Fatty Liver Disease and Recent Guideline Updates
Watch a video presentation of this article
- Open Access
- 1 March 2018
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 11 (3) , 73-76
The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus
- 1 March 2018
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 11 (3) , 73-76
Open AccessThe link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus
- Open Access
- 11 September 2017
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 4 (1) , e000157
Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?
Introduction To assess the outcomes of immediate LDT versus observation strategies for T1 hepatocellular carcinoma (HCC) with respect to progression beyond Milan and survival. Method T1 HCCs were retrospectively reviewed from a multidisciplinary tumour board database between September 2007 and May 2015. In the observation group, T1 lesions were observed until the tumour grew to meet T2 criteria (=2 cm). The treatment group consisted of T1 lesions treated at diagnosis with liver directed therapy (LDT). Kaplan-Meier plots were constructed for tumour progression beyond Milan and overall survival. Results 87 patients (observation n=56; LDT n=31) were included in the study. A total of 22% (n=19) of patients progressed beyond Milan with no difference in progression between treatment and observation groups (19% vs 23%, p=0.49). Median time to progression beyond Milan was 16 months. Overall transplantation rate was 22% (observation group n=16; treatment group n=3, p=0.04). Median survival was 55 months with LDT versus 36 months in the observation group (p=0.22). In patients who progressed to T2 (n=60), longer time to T2 progression was a predictor of improved survival (HR=0.94, 95% CI 0.88 to 0.99, p=0.03). Conclusions Immediate LDT of T1 lesions was not associated with increased risk of progression beyond Milan criteria when compared with an observation approach. Longer time to T2 progression was associated with increased survival and may be a surrogate for favourable tumour biology.
- 11 September 2017
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 4 (1) , e000157
Open AccessClose observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?
Introduction To assess the outcomes of immediate LDT versus observation strategies for T1 hepatocellular carcinoma (HCC) with respect to progression beyond Milan and survival. Method T1 HCCs were retrospectively reviewed from a multidisciplinary tumour board database between September 2007 and May 2015. In the observation group, T1 lesions were observed until the tumour grew to meet T2 criteria (=2 cm). The treatment group consisted of T1 lesions treated at diagnosis with liver directed therapy (LDT). Kaplan-Meier plots were constructed for tumour progression beyond Milan and overall survival. Results 87 patients (observation n=56; LDT n=31) were included in the study. A total of 22% (n=19) of patients progressed beyond Milan with no difference in progression between treatment and observation groups (19% vs 23%, p=0.49). Median time to progression beyond Milan was 16 months. Overall transplantation rate was 22% (observation group n=16; treatment group n=3, p=0.04). Median survival was 55 months with LDT versus 36 months in the observation group (p=0.22). In patients who progressed to T2 (n=60), longer time to T2 progression was a predictor of improved survival (HR=0.94, 95% CI 0.88 to 0.99, p=0.03). Conclusions Immediate LDT of T1 lesions was not associated with increased risk of progression beyond Milan criteria when compared with an observation approach. Longer time to T2 progression was associated with increased survival and may be a surrogate for favourable tumour biology.
- 1 November 2013
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 47 (10) , e91-e95
Analysis of Site Performance in Academic-based and Community-based Centers in the IDEAL Study
Goals: To evaluate differences in metrics of quality and site performance in academic and community sites participating in a multicenter study. Background: In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study, the participation of 76 academic-based and 42 community-based US centers provided an opportunity to evaluate various metrics of quality and site performance. Study: A secondary data analysis of the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study was performed. There were 3070 treatment-naive, hepatitis C virus genotype 1 infected patients were included. We retrospectively evaluated rates of screen failure, completion, and discontinuation of treatment and follow-up, treatment adherence, and virologic response by site type. Results: Of the patients screened, 63% and 37% were in academic and community centers, respectively. Screen failure rates were similar (30% to 32%). End-of-treatment response, relapse, and sustained virologic response (SVR) rates in academic and community centers did not differ. SVR was achieved in 40% of patients at academic sites and 39% at community sites. Adherence to ≥80% of peginterferon-α and ribavirin dosing for ≥80% assigned duration was also similar (46% in academic and 47% in community centers). In both academic and community centers, 54% of patients completed treatment; there were similar discontinuation rates for treatment failure and adverse events. Conclusions: There were no significant differences in adherence, adverse events, rates of discontinuation, on-treatment virologic response, and SVR when comparing academic and community sites. The performance of academic-based and experienced community-based sites in clinical trials is largely similar for the treatment of chronic hepatitis C.
- 1 November 2013
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 47 (10) , e91-e95
Analysis of Site Performance in Academic-based and Community-based Centers in the IDEAL Study
Goals: To evaluate differences in metrics of quality and site performance in academic and community sites participating in a multicenter study. Background: In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study, the participation of 76 academic-based and 42 community-based US centers provided an opportunity to evaluate various metrics of quality and site performance. Study: A secondary data analysis of the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study was performed. There were 3070 treatment-naive, hepatitis C virus genotype 1 infected patients were included. We retrospectively evaluated rates of screen failure, completion, and discontinuation of treatment and follow-up, treatment adherence, and virologic response by site type. Results: Of the patients screened, 63% and 37% were in academic and community centers, respectively. Screen failure rates were similar (30% to 32%). End-of-treatment response, relapse, and sustained virologic response (SVR) rates in academic and community centers did not differ. SVR was achieved in 40% of patients at academic sites and 39% at community sites. Adherence to ≥80% of peginterferon-α and ribavirin dosing for ≥80% assigned duration was also similar (46% in academic and 47% in community centers). In both academic and community centers, 54% of patients completed treatment; there were similar discontinuation rates for treatment failure and adverse events. Conclusions: There were no significant differences in adherence, adverse events, rates of discontinuation, on-treatment virologic response, and SVR when comparing academic and community sites. The performance of academic-based and experienced community-based sites in clinical trials is largely similar for the treatment of chronic hepatitis C.